Calliditas Therapeutics Says FDA Granted Priority Review of Tarpeyo for Treatment of Immunoglobulin A Nephropathy
Calliditas Therapeutics Says FDA Granted Priority Review of Tarpeyo for Treatment of Immunoglobulin A Nephropathy
Calliditas Therapeutics表示,美国食品药品管理局已批准对用于治疗A型免疫球蛋白肾病的Tarpeyo进行优先审查
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册